Skip to main content

All Policy Documents

Title
 Abdominoplasty/Apronectomy (following significant weight loss) Referral proforma PP45 (Word, 92Kb)
 Abdominoplasty/Apronectomy following Significant Weight Loss, Policy Position Statement (PP45), March 2025 (PDF, 145Kb)
 Adult Congenital Heart Disease Services (Levels 1 and 2) for people aged 16 and over, Service Specification (CP214). June 2022 (PDF, 423Kb)
 Adult Neurosurgery, Service Specification, (CP178), March 2023 (PDF, 731Kb)
 Adult Thoracic Surgery, Service Specification (CP144), September 2020 (PDF, 450Kb)
 All Wales Posture and Mobility, Service Specification (CP59). April 2017 (PDF, 1.5Mb)
 Allogeneic Haematopoietic Stem Cell Transplant (HSCT) for people of all ages with Sickle Cell Disease (SCD), Commissioning Policy (CP224). November 2021 (PDF, 443Kb)
 Alternative and Augmentative Communication (AAC), Commissioning Policy (CP93a), May 2019 (PDF, 570Kb)
 Asfotase alfa for treating paediatric-onset hypophosphatasia in children aged under 16 years, Policy Position Statement (PP156), November 2023 (PDF, 263Kb)
 Ataluren for Treating Duchenne Muscular Dystrophy with a Nonsense Mutation in the Dystrophin Gene Policy Position Statement (PP118), July 2023 (PDF, 217Kb)
 Atidarsagene Autotemcel for Treating Metachromatic Leukodystrophy in Children, Policy Position Statement, (PP257), April 2023 (PDF, 180Kb)
 Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (all ages), (PP162) March 2025 (PDF, 236Kb)
 Berotralstat for preventing recurrent attacks of hereditary angioedema for people aged 12 years and older, Policy Position Statement (PP236). June 2022 (PDF, 277Kb)
 Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis Type 2 (now known as NF2-related vestibular schwannomatosis) (all ages) (CP254), August 2023 (PDF, 440Kb)
 Bleeding Disorders (All Ages), Service Specification (CP77), June 2022 (PDF, 343Kb)
 Body Contouring, Commissioning Policy (CP44). March 2025 (PDF, 293Kb)
 Brachytherapy in the Treatment of Localised Prostate Cancer, Commissioning Policy (CP01). September 2022 (PDF, 368Kb)
 Breast Surgery Procedures, Commissioning Policy (CP69). March 2025 (PDF, 251Kb)
 Burosumab for Treating X-linked Hypophosphataemia in Children and Young People, Policy Position (PP177), May 2019.pdf (PDF, 557Kb)
 Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 and older), Policy Position Statement, (PP228). January 2022. (PDF, 324Kb)
 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome or Lennox–Gastaut syndrome in people aged 2 years and older, Policy Position Statement (PP203), July 2024 (PDF, 309Kb)
 Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 for children aged under 16 years, Policy Position Statement (PP262), November 2023 (PDF, 233Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Gilead Axicabtagene Ciloleucel (Yescarta®) Service Specification (CP175), March 2019 (PDF, 514Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Novartis Tisagenlecleucel (Kymriah ®) Service Specification. (CP176), March 2019 (PDF, 571Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Policy Position Statement, (PP185). April 2023 (PDF, 254Kb)
 Circumcision for Children, Commissioning Policy (CP34). December 2024 (PDF, 344Kb)
 Cleft Lip and/or Palate including Non-Cleft Velopharyngael Dysfuncion: All Ages, Service Specification (CP186), November 2025 (PDF, 591Kb)
 Clinical Trials (all ages), Commissioning Policy (CP164), July 2023 (PDF, 318Kb)
 Cochlear Implant for Children and Adults with Severe to Profound Deafness, Commissioning Policy, (CP35), May 2020 (PDF, 227Kb)
 Complex Devices Implantable Cardioverter Defibrillators and Cardiac Resynchronisation Therapy for arrhythmias and heart failure (PP151).pdf March 2025 (PDF, 234Kb)
 Corneal cross-linking for keratoconus in children (from birth until their 16th birthday) commissioning policy, (CP271), October 2023 (PDF, 328Kb)
 Crizanlizumab for Preventing Sickle Cell Crisis in Sickle Cell Disease (SCD) in people aged 16 and over, Policy Position Statement (PP234), February 2023 (PDF, 281Kb)
 Cystic Fibrosis Modulator therapies Policy Position Statement, (PP198). March 2022 (PDF, 354Kb)
 Cystic Fibrosis: Adults and Young People (CP193), Service Specification. Jan 2025 (PDF, 391Kb)
 Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis and Pseudomyxoma Peritonei, Policy Position Statement, (PP90). September 2015 (PDF, 239Kb)
 Deep Brain Stimulation, Commissioning Policy (CP28), July 2024 (PDF, 384Kb)
 Dexrazoxane for Preventing Cardiotoxicity in Children (Aged Under 16 Years Old) Receiving High-Dose Anthracyclines or Related Drugs for the Treatment of Cancer, Policy Position Statement (PP253), February 2023 (PDF, 265Kb)
 Dialysis Away from Base (DAFB) (Holiday Dialysis) (CP33) December 2024 (Word, 205Kb)
 Drug Treatment for Lysosomal Storage Disorders (All ages), Commissioning Policy (CP55). January 2023 (PDF, 420Kb)
 Eating Disorder Specialised Services Tier 4, Commissioning Policy (CP20). November 2011 (PDF, 320Kb)
 Eculizimab for Atypical Haemolytic Uraemic Syndrome (aHUS), (CP98), November 2025 (PDF, 284Kb)
 Eculizumab in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), Commissioning Policy, (CP152), July 2023 (PDF, 641Kb)
 Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (PP281) February 2027 (PDF, 212Kb)
 Electrophysiology and Ablation Services (16 years and older), Commissioning policy (CP197a). January 2025 (PDF, 347Kb)
 Electrophysiology and Ablation Services (16 years and older), Service Specification (CP197b) January 2025 (PDF, 331Kb)
 Emicizumab as prophylaxis in people with congenital haemophilia A with Factor VIII inhibitors (all ages), Policy Position Statement (PP167). November 2018 (PDF, 316Kb)
 Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors, Policy Position Statement, (PP189), November 2023 (PDF, 288Kb)
 Everolimus for the prevention of organ rejection following heart transplantation, Policy Position Statement (PP103), July 2019 (PDF, 164Kb)
 Extra corporeal membrane oxygenation (ECMO) service for adults with cardiac failure, Policy Position Statement, (PP102). July 2019 (PDF, 141Kb)
 Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplant (BTLT) (All Ages), Policy Position Statement, (PP251), February 2023 (PDF, 288Kb)
 Facial Surgery procedures, Commissioning Policy (CP43). March 2025 (PDF, 325Kb)
 Facial Surgery procedures: Referral proforma Blepharoplasty (CP43) (Word, 92Kb)
 Facial Surgery procedures: Referral proforma Face lift/brow lift (CP43) (Word, 92Kb)
 Facial Surgery procedures: Referral proforma Miscellaneous (CP43) (Word, 91Kb)
 Facial Surgery procedures: Referral proforma Pinnaplasty (CP43) (Word, 91Kb)
 Facial Surgery procedures: Referral proforma Rhinoplasty (CP43) (Word, 92Kb)
 Gatekeeping, Placement and Case Management for Specialised Mental Health Services, CP232, June 2022 (PDF, 399Kb)
 Gender Identity Service for Adults (non surgical) Commissioning Policy (CP182a) July 2024 (PDF, 543Kb)
 Gender Identity Service for Adults (non surgical) Service Specification (CP182b) July 2024 (PDF, 578Kb)
 Genomics Service Specification (CP99). June 2022 (PDF, 572Kb)
 Genomic Testing, Policy Position Statement, (PP184). June 2020 (PDF, 231Kb)
 Givosiran for Treating Acute Hepatic Porphyria for People Aged 12 Years and Older, (PP252), Policy Position Statement, April 2023 (PDF, 131Kb)
 Haematopoietic stem cell transplantation for adults, Service Specification (CP79). January 2020 (PDF, 295Kb)
 Haematopoietic stem cell transplantation, Policy Position Statement, (PP142). January 2020 (PDF, 553Kb)
 Hepatobiliary Surgery, Service Specification (CP73). November 2021 (PDF, 344Kb)
 Home administered Parenteral Nutrition (HPN), Commissioning Policy (CP24). August 2014 (PDF, 202Kb)
 Hyperbaric Oxygen Therapy, Commissioning Policy (CP07), July 2023 (PDF, 363Kb)
 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei, Commissioning Policy (CP02), March 2025 (PDF, 202Kb)
 Inherited White Matter Disorders Policy Position Statement (PP239) May 2023 (PDF, 565Kb)
 In-patient Child and Adolescent Mental Health Services (CAMHS): General Adolescent (GAU) and Extra Care Area (ECA), Service Specification (CP150), November 2026 (PDF, 547Kb)
 Living Donor Expenses, Commissioning Policy (CP30), December 2026 (PDF, 307Kb)
 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (NETs), Policy Position Statement (PP195), November 2026 (PDF, 334Kb)
 Lymphovenous Anastamosis (LVA) microsurgery for Primary and Secondary Lymphoedema, Commissioning Policy (CP87b). August 2015 (PDF, 501Kb)
 Lymphovenous Anastamosis (LVA) microsurgery for Primary and Secondary Lymphoedema, Service Specification (CP87a). August 2015 (PDF, 380Kb)
 Major Trauma Centre, Appendix 1, Commissioning & governance arrangements for partner organisations within the Major Trauma Network. (CP188) February 2021 (PDF, 345Kb)
 Major Trauma Centre, Appendix 2: Quality Indicators. (CP188) February 2021 (PDF, 665Kb)
 Major Trauma Centre, Service Specification (CP188), February 2021 (PDF, 665Kb)
 Mechanical Thrombectomy for the treatment of acute Ischaemic Stroke, Commissioning Policy (CP168). March 2022 (PDF, 816Kb)
 Microprocessor controlled prosthetic knees, Commissioning Policy (CP218). December 2021 (PDF, 388Kb)
 National Acute Porphyria, Service Specification (CP166). February 2025 (PDF, 274Kb)
 Neuropsychiatric Rehabilitation (Specialised), Commissioning Policy, (CP128), August 2024 (PDF, 327Kb)
 New Treatment Fund (CP159) January 2025 (PDF, 354Kb)
 NHS Wales Specialist Children and Young People Gender Identity Services (PDF, 1.7Mb)
 Nusinersen for treating spinal muscular atrophy, Policy Position Statement (PP191), November 2026 (PDF, 400Kb)
 Obesity Surgery for Complex and Severe Obesity Level 4 (Adults), Commissioning Policy, (CP29a), March 2023 (PDF, 316Kb)
 Obesity Surgery for Complex and Severe Obesity- Level 4 (Adults), Service Specification (CP29b), March 2023 (PDF, 383Kb)
 Odevixibat for Treating Progressive Familial Intrahepatic Cholestasis, Policy Position Statement, (PP249), February 2023 (PDF, 193Kb)
 Paediatric Endocrinology, Service Specification (CP163), July 2024 (PDF, 283Kb)
 Paediatric Epilepsy, Commissioning Policy (CP174), September 2022 (PDF, 487Kb)
 Paediatric Nephrology Service Specification, CP169 (March 2021) (PDF, 443Kb)
 Pasireotide for Cushing's Disease, Policy Position (PP155), July 2019 (PDF, 252Kb)
 Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors (NET) in Adults, Service Specification, (CP266), March 2023 (PDF, 300Kb)
 Percutaneous Mitral Valve Leaflet repair for primary degenerative mitral regurgitation in adults, Policy Position Statement (PP206). June 2021 (PDF, 476Kb)
 Perinatal post-mortem investigation of fetal and neonatal deaths (England, Scotland and Wales). Interim Clinical Commissioning Urgent Policy Statement. October 2022 (PDF, 304Kb)
 Personalised External Aortic Root Support (PEARS) for surgical management of enlarged aortic root (adults), Policy Position Statement, (PP104). March 2025 (PDF, 195Kb)
 Pipeline Embolisation Devices used for the treatment of Intracranial Aneurysms (Complex Giant or Large Intracranial Aneurysms), Commissioning Policy (CP101). July 2015 (PDF, 352Kb)
 Plerixafor for stem cell mobilisation, Policy Position Statement (PP154), July 2024 (PDF, 208Kb)
 Positron Emission Tomography (PET) Commissioning Policy (CP50a), April 2023 (PDF, 356Kb)
 Positron Emission Tomography (PET), Service Specification (CP50b). September 2020 (PDF, 514Kb)
 Preimplantation Genetic Diagnosis (PGD), Commissioning Policy (CP37). March 2025 (PDF, 445Kb)
 Prosthetic Provision, Service Specification (CP89). March 2025 (PDF, 433Kb)
 Proton Beam Therapy for adults with cancer Commissioning Policy (CP147), July 2023 (PDF, 279Kb)
 Proton Beam Therapy for children, teenagers and young adults (TYA) with cancer, Commissioning Policy (CP148), April 2023 (PDF, 231Kb)
 Radiofrequency Ablation (RFA) for the Management of Barrett's Oesophagus, Commissioning Policy (CP183a). May 2020 (PDF, 318Kb)
 Radiofrequency Ablation (RFA) for the Management of Barrett's Oesophagus, Service Specification (CP183b). May 2020 (PDF, 348Kb)
 Recreational and Sport Prosthetics for a Child or Young Adult up to the age of 25, Commissioning Policy (CP221). November 2021 (PDF, 402Kb)
 Revision Surgery for Severe and Complex Obesity (Adults), Commissioning Policy, (CP259), May 2023 (PDF, 273Kb)
 Risdiplam for Spinal Muscular Atrophy for people aged under 16 years, Policy Position Statement (PP240). May 2022 (PDF, 361Kb)
 Rituximab and Eculizumab for the Prevention and Management of Delayed Haemolytic Transfusion Reactions and Hyperhaemolysis in people with Hereditary Anaemias, Policy Position Statement (PP237), February 2023 (PDF, 438Kb)
 Salvage Cryotherapy for Prostate Cancer, Policy Position Statement, (PP173). June 2020 (PDF, 188Kb)
 Sapropterin for treating hyperphenylalaninaemia (HPA) in phenylketonuria (PKU) and tetrahydrobiopterin (BH4) disorders, Policy Position (PP223), January 2023 (PDF, 464Kb)
 Selective internal radiation therapies (SIRT) for treating adults with hepatocellular carcinoma, Policy Position Statement, (PP227). November 2021 (PDF, 303Kb)
 Selexipag for the Treatment of Pulmonary Arterial Hypertension (Adults), Policy Position (PP105), March 2019.pdf (PDF, 255Kb)
 Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over, Policy Position Statement (PP267), September 2023 (PDF, 228Kb)
 Services for Children with Cancer, (CP86), December 2024 (PDF, 545Kb)
 Sickle Cell Disorders, Thalassaemia Disorders and other Rare Hereditary Anaemias, Service Specification (CP179). December 2020 (PDF, 494Kb)
 Soft Tissue Sarcoma, Service Specification (CP149), June 2020 (PDF, 396Kb)
 South Wales Neonatal Transport Operational Delivery Network, (CP244) October 2022 (PDF, 303Kb)
 Specialised Fetal Medicine, Commissioning Policy, (CP97), October 2023 (PDF, 372Kb)
 Specialised Immunology, Service Specification (CP78). April 2014 (PDF, 950Kb)
 Specialised Paediatric Gastroenterology, Hepatology and Nutrition (PGHAN) Service Specification (CP211) May 2023 (PDF, 759Kb)
 Specialised Paediatric Neurological Rehabilitation, Commissioning Policy (CP160), November 2024 (PDF, 359Kb)
 Specialised Paediatric Rheumatology Service Specification (CP172). November 2021 (PDF, 475Kb)
 Specialised Services Clinical Access Policy: Enhanced Image Guided Brachytherapy (IGBT) Service for the Treatment of Gynaecological Malignancies (CP75), May 2017 (PDF, 755Kb)
 Specialised Services Policy: Extracorporeal Photophoresis (ECP) for the Treatment of Chronic Graft versus Host Disease in Adults (CP91), November 2015 (PDF, 658Kb)
 Specialised Services Policy: Extracorporeal Photophoresis (ECP) for the Treatment of Cutaneous T-cell Lymphoma (CP92), November 2015 (PDF, 624Kb)
 Specialist Fertility Services, Commissioning Policy (CP38), April 2025 (PDF, 360Kb)
 Specialist Perinatal Mental Health Inpatient Service (Mother and Baby Unit) CP201, Service Specification. April 2021 (PDF, 474Kb)
 Specialist Spinal Cord Injury Rehabilitation, Commissioning Policy (CP141). February 2025 (PDF, 438Kb)
 Specialist Neurological Rehabilitation, Commissioning Policy (CP140), November 2024 (PDF, 433Kb)
 Spinal Services Operational Delivery Network (CP241) June 2022 (PDF, 381Kb)
 Stereotactic Ablative Body Radiotherapy (SABR) for the management of Non-Small Cell Lung Cancer in people aged 18 years and above, Commissioning Policy (CP76) June 2023 (PDF, 525Kb)
 Stereotactic Ablative Body Radiotherapy (SABR) Service Specification (CP219) June 2021 (PDF, 356Kb)
 Stereotactic ablative radiotherapy (SABR) for patients with hepatocellular carcinoma (HCC) (Adults), Commissioning Policy (CP124), December 2021 (PDF, 398Kb)
 Stereotactic Ablative Radiotherapy (SABR) in the treatment of Oligometastatic disease, Commissioning Policy (CP121). October 2021 (PDF, 387Kb)
 Stereotactic Radiosurgery for Adults, Teenagers and Young Adults (TYA) (CP22) June 2020 (PDF, 716Kb)
 Teduglutide for Treating Short Bowel Syndrome, Policy Position Statement, (PP265), May 2023 (PDF, 130Kb)
 Tier 4 Forensic Child and Adolescent Mental Health Service (Forensic Adolescent Consultation Service – Consultation and Advice for Child and Adolescent Mental Health Services), Service Specification, (CP222), August 2023 (PDF, 523Kb)
 Tofacitinib for treating juvenile idiopathic arthritis in people aged 2 to 16 years, Policy Position Statement (PP229). May 2022 (PDF, 311Kb)
 Trans-catheter Aortic Valve Implantation (TAVI) for Severe Symptomatic Aortic Stenosis (SSAS), Commissioning Policy (CP58), March 2019 (PDF, 295Kb)
 Transcranial magnetic resonance guided focused ultrasound (TcMRgFUS) thalamotomy for treatment of medication-refractory essential tremor for people aged 18 and over, Policy Position Statement, (PP258), August 2023 (PDF, 298Kb)
 Trauma Operational Delivery Network, Service Specification (CP199). February 2021 (PDF, 663Kb)
 Treatment of Benign Skin Conditions, Commissioning Policy (CP42). March 2025 (PDF, 291Kb)
 Treatment of Benign Skin Conditions, Referral Proforma Resurfacing (CP42) (Word, 91Kb)
 Treatment options for Transthyretin Amyloidosis in Adults, Policy Position Statement (PP187), September 2023 (PDF, 307Kb)
 Vagal Nerve Stimulation, Commissioning Policy (CP23), July 2023 (PDF, 688Kb)
 Volanesorsen for treating familial chylomicronaemia syndrome, Policy Position Statement, (PP217). October 2021 (PDF, 285Kb)
 Vonicog alfa for the treatment and prevention of bleeding in people of all ages with von Willebrand disease, Policy Position Statement (PP215) (PDF, 353Kb)
 Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations (PP196), March 2020 (PDF, 277Kb)
 War Veterans – Enhanced Prosthetic Provision, Commissioning Policy (CP49), October 2020 (PDF, 408Kb)
 Welsh Artificial Eye Service (WAES) (All Ages), Service Specification (CP238), December 2022 (PDF, 453Kb)